Amyotrophic lateral sclerosis （ALS） is a chronic progressive disease with unknown etiology and pathogenesis， and there are still no effective biomarkers to assist in the diagnosis， progression judgment， and prognostic evaluation of the disease. The research on biomarkers can deepen the understanding of disease by exploring pathophysiological mechanisms and help with disease diagnosis， classification， pharmacodynamic detection， and identification of new drug targets， thereby providing a direction for the implementation of new therapies. ［Citation:Journal of International Neurology and Neurosurgery, 2021, 48(4): 392-395.］